NasdaqCM:TGTXBiotechs
Why TG Therapeutics (TGTX) Is Up 5.1% After Raising 2025 Revenue Guidance and Reporting Earnings
TG Therapeutics recently reported strong second quarter results, with US$141.15 million in revenue and a sharp rise in net income, and raised its full-year 2025 revenue guidance to approximately US$585 million.
The company also filed multiple shelf registrations totaling up to US$139.45 million, including an ESOP-related offering, indicating preparations for potential future capital needs alongside improving financial performance.
We’ll now explore how the raised annual guidance and robust...